|
1
|
Ding R, Shi J, Pabon K and Scotto KW:
Xanthines down-regulate the drug transporter ABCG2 and reverse
multidrug resistance. Mol Pharmacol. 81:328–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ishikawa T, Saito H, Hirano H, Inoue Y and
Ikegami Y: Human ABC transporter ABCG2 in cancer chemotherapy: drug
molecular design to circumvent multidrug resistance. Methods Mol
Biol. 910:267–278. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kalalinia F, Elahian F, Hassani M,
Kasaeeian J and Behravan J: Phorbol ester TPA modulates
chemoresistance in the drug sensitive breast cancer cell line MCF-7
by inducing expression of drug efflux transporter ABCG2. Asian Pac
J Cancer Prev. 13:2979–2984. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mo W and Zhang JT: Human ABCG2: structure,
function, and its role in multidrug resistance. Int J Biochem Mol
Biol. 3:1–27. 2012.PubMed/NCBI
|
|
5
|
Natarajan K, Xie Y, Baer MR and Ross DD:
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer
drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sodani K, Tiwari AK, Singh S, et al:
GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse
ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol.
83:1613–1622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu CP, Hsieh CH and Wu YS: The emergence
of drug transporter-mediated multidrug resistance to cancer
chemotherapy. Mol Pharm. 8:1996–2011. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xia CQ and Smith PG: Drug efflux
transporters and multidrug resistance in acute leukemia:
therapeutic impact and novel approaches to mediation. Mol
Pharmacol. 82:1008–1021. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oguri T, Ozasa H, Uemura T, et al:
Preclinical rationale for synergistic interaction of pemetrexed and
cytotoxic nucleoside analogues. Oncol Lett. 4:571–575.
2012.PubMed/NCBI
|
|
10
|
Oplustilova L, Wolanin K, Mistrik M, et
al: Evaluation of candidate biomarkers to predict cancer cell
sensitivity or resistance to PARP-1 inhibitor treatment. Cell
Cycle. 11:3837–3850. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spanswick VJ, Lowe HL, Newton C, et al:
Evidence for different mechanisms of ‘unhooking’ for melphalan and
cisplatin-induced DNA interstrand cross-links in vitro and in
clinical acquired resistant tumour samples. BMC Cancer.
12:4362012.
|
|
12
|
Yang YI, Lee KT, Park HJ, et al:
Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer
cells through downregulation of the Akt and NFκB pathway.
Carcinogenesis. 12:2488–2498. 2012.PubMed/NCBI
|
|
13
|
Hagiya Y, Endo Y, Yonemura Y, et al:
Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette
(ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based
photocytotoxicity of gastric cancer cells in vitro. Photodiagnosis
Photodyn Ther. 9:204–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Flores-Martín J, Rena V, Márquez S,
Panzetta-Dutari GM and Genti-Raimondi S: StarD7 knockdown modulates
ABCG2 expression, cell migration, proliferation, and
differentiation of human choriocarcinoma JEG-3 cells. PLoS One.
7:e441522012.PubMed/NCBI
|
|
15
|
Shen B, Dong P, Li D and Gao S: Expression
and function of ABCG2 in head and neck squamous cell carcinoma and
cell lines. Exp Ther Med. 2:1151–1157. 2011.PubMed/NCBI
|
|
16
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Omran OM: The prognostic value of breast
cancer resistance protein (BCRP/ABCG2) expression in breast
carcinomas. J Environ Pathol Toxicol Oncol. 31:367–376. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Campos CR, Schröter C, Wang X and Miller
DS: ABC transporter function and regulation at the blood-spinal
cord barrier. J Cereb Blood Flow Metab. 32:1559–1566. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Decleves X, Jacob A, Yousif S, Shawahna R,
Potin S and Scherrmann JM: Interplay of drug metabolizing CYP450
enzymes and ABC transporters in the blood-brain barrier. Curr Drug
Metab. 12:732–741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kania KD, Wijesuriya HC, Hladky SB and
Barrand MA: Beta amyloid effects on expression of multidrug efflux
transporters in brain endothelial cells. Brain Res. 1418:1–11.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Masereeuw R and Russel FG: Regulatory
pathways for ATP-binding cassette transport proteins in kidney
proximal tubules. AAPS J. 14:883–894. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miller DW, Hinton M and Chen F: Evaluation
of drug efflux transporter liabilities of darifenacin in cell
culture models of the blood-brain and blood-ocular barriers.
Neurourol Urodyn. 30:1633–1638. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pinzón-Daza M, Garzón R, Couraud P, et al:
The association of statins plus LDL receptor-targeted
liposome-encapsulated doxorubicin increases in vitro drug delivery
across blood-brain barrier cells. Br J Pharmacol. 167:1431–1447.
2012.PubMed/NCBI
|
|
24
|
Kobayashi D, Ieiri I, Hirota T, et al:
Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein
expression in human placenta. Drug Metab Dispos. 33:94–101. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krishnamurthy P and Schuetz JD: Role of
ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol.
46:381–410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan G, Giri N and Elmquist WF: Abcg2/Bcrp1
mediates the polarized transport of antiretroviral nucleosides
abacavir and zidovudine. Drug Metab Dispos. 35:1165–1173. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mao Q and Unadkat JD: Role of the breast
cancer resistance protein (ABCG2) in drug transport. AAPS J.
7:E118–E133. 2005. View Article : Google Scholar : PubMed/NCBI
|
